RxDoctor Payments Data

Nicholas Dodge, MD

Internal Medicine · Dunmore, PANPI 1679534226

Payments from drug & device makers

$521in general payments, 2019–2025

Across 21 payments — averaging $24.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$174
  • Lilly USA, LLC$131
  • Sumitomo Pharma America, Inc.$97
  • Otsuka America Pharmaceutical, Inc.$37
  • Pfizer$29
  • Amarin Pharma, Inc.$25
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$34767%
  • Education$17433%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$521 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$193,148
Medicare patients
348
Services billed
1,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban814$307,286
OzempicSemaglutide133$142,148
JardianceEmpagliflozin241$108,970
JanuviaSitagliptin Phosphate136$54,851
MyrbetriqMirabegron151$52,164
Chlorpromazine Hcl67$33,991
XareltoRivaroxaban81$32,398
KeppraLevetiracetam13$30,408
ProliaDenosumab16$29,941
Atorvastatin Calcium1,519$27,174
EntrestoSacubitril/Valsartan51$25,116
Lagevrio (Eua)Molnupiravir23$21,908
TradjentaLinagliptin56$21,402
Aripiprazole180$21,281
NuedextaDextromethorphan Hbr/Quinidine14$20,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$307,286814 claims
Astellas Pharma US IncMyrbetriq$174$52,164151 claims
Johnson & JohnsonXarelto$15$32,39881 claims
Avanir Pharmaceuticals, Inc.Nuedexta$13$20,63114 claims
Otsuka America Pharmaceutical, Inc.Rexulti$37$17,24814 claims
Lilly USA, LLCMounjaro$131$14,47912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Dunmore

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →